Ascendis Pharma A/S (NASDAQ:ASND) Receives $173.25 Average Price Target from Analysts

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $173.25.

Several equities analysts have recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Ascendis Pharma A/S in a research report on Wednesday, December 20th. They set a "buy" rating and a $150.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, April 1st. JPMorgan Chase & Co. increased their target price on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an "overweight" rating in a research report on Tuesday, April 2nd. Wells Fargo & Company increased their target price on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an "overweight" rating in a research report on Friday, March 15th. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Monday, December 25th.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the business. US Bancorp DE lifted its stake in Ascendis Pharma A/S by 35.2% during the fourth quarter. US Bancorp DE now owns 284 shares of the biotechnology company's stock valued at $36,000 after buying an additional 74 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock valued at $42,000 after purchasing an additional 91 shares during the period. GAMMA Investing LLC increased its holdings in shares of Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 102 shares during the period. Envestnet Asset Management Inc. increased its holdings in Ascendis Pharma A/S by 3.4% in the third quarter. Envestnet Asset Management Inc. now owns 3,226 shares of the biotechnology company's stock worth $333,000 after buying an additional 105 shares during the last quarter. Finally, Guggenheim Capital LLC increased its holdings in Ascendis Pharma A/S by 7.2% in the first quarter. Guggenheim Capital LLC now owns 2,008 shares of the biotechnology company's stock worth $236,000 after buying an additional 135 shares during the last quarter.

Ascendis Pharma A/S Stock Up 3.2 %

ASND stock traded up $4.79 during trading on Tuesday, hitting $153.67. 295,398 shares of the company's stock traded hands, compared to its average volume of 377,075. Ascendis Pharma A/S has a 52 week low of $66.03 and a 52 week high of $161.00. The stock has a fifty day moving average price of $147.80 and a two-hundred day moving average price of $121.35.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. The firm had revenue of $148.62 million during the quarter, compared to analyst estimates of $97.02 million. Research analysts predict that Ascendis Pharma A/S will post -4.16 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.